Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1950 1
1951 1
1952 1
1972 1
1973 1
1978 1
1980 1
1982 4
1983 3
1984 1
1985 6
1986 3
1987 1
1988 3
1989 7
1990 9
1991 5
1992 2
1993 8
1994 2
1995 11
1996 5
1997 4
1998 7
1999 3
2000 5
2001 7
2002 7
2003 14
2004 20
2005 30
2006 34
2007 42
2008 40
2009 39
2010 44
2011 52
2012 67
2013 70
2014 70
2015 66
2016 71
2017 77
2018 68
2019 57
2020 77
2021 67
2022 60
2023 63
2024 27

Text availability

Article attribute

Article type

Publication date

Search Results

1,139 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Myasthenia gravis: subgroup classification and therapeutic strategies.
Gilhus NE, Verschuuren JJ. Gilhus NE, et al. Lancet Neurol. 2015 Oct;14(10):1023-36. doi: 10.1016/S1474-4422(15)00145-3. Lancet Neurol. 2015. PMID: 26376969 Review.
Myasthenia gravis is an autoimmune disease that is characterised by muscle weakness and fatigue, is B-cell mediated, and is associated with antibodies directed against the acetylcholine receptor, muscle-specific kinase (MUSK), lipoprotein-related protein 4 (LRP4), or agrin …
Myasthenia gravis is an autoimmune disease that is characterised by muscle weakness and fatigue, is B-cell mediated, and is associated with …
Myasthenia gravis: MuSK MG, late-onset MG and ocular MG.
Deymeer F. Deymeer F. Acta Myol. 2020 Dec 1;39(4):345-352. doi: 10.36185/2532-1900-038. eCollection 2020 Dec. Acta Myol. 2020. PMID: 33458590 Free PMC article. Review.
Three relatively less frequently seen subtypes of MG are the subject of this review: MG with anti-MuSK antibodies (MuSK MG), non-thymomatous late-onset MG (LOMG), and ocular MG (OMG). In addition to reviewing the literature, mainly from a clinical point of view, our …
Three relatively less frequently seen subtypes of MG are the subject of this review: MG with anti-MuSK antibodies (MuSK MG), n …
Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.
Vakrakou AG, Karachaliou E, Chroni E, Zouvelou V, Tzanetakos D, Salakou S, Papadopoulou M, Tzartos S, Voumvourakis K, Kilidireas C, Giannopoulos S, Tsivgoulis G, Tzartos J. Vakrakou AG, et al. Front Immunol. 2023 Jul 26;14:1212757. doi: 10.3389/fimmu.2023.1212757. eCollection 2023. Front Immunol. 2023. PMID: 37564637 Free PMC article. Review.
IgG4 class autoantibodies are impotent to fix complement and only weakly bind Fc-receptors expressed on immune cells and exert their pathogenicity via interfering with the interaction between their targets and binding partners (e.g. between MuSK and LRP4). Cardinal differe …
IgG4 class autoantibodies are impotent to fix complement and only weakly bind Fc-receptors expressed on immune cells and exert their pathoge …
Myasthenia gravis: an update for the clinician.
Sieb JP. Sieb JP. Clin Exp Immunol. 2014 Mar;175(3):408-18. doi: 10.1111/cei.12217. Clin Exp Immunol. 2014. PMID: 24117026 Free PMC article. Review.
Myasthenia gravis should be classified according to the antibody specificity [acetylcholine, muscle-specific receptor tyrosine kinase (MuSK), low-density lipoprotein receptor-related protein 4 (LRP4), seronegative], thymus histology (thymitis, thymoma, atrophy), age at ons …
Myasthenia gravis should be classified according to the antibody specificity [acetylcholine, muscle-specific receptor tyrosine kinase (Mu …
Myasthenic crisis.
Claytor B, Cho SM, Li Y. Claytor B, et al. Muscle Nerve. 2023 Jul;68(1):8-19. doi: 10.1002/mus.27832. Epub 2023 Apr 28. Muscle Nerve. 2023. PMID: 37114503 Review.
MG patients with a history of MC, severe disease, oropharyngeal weakness, muscle-specific kinase (MuSK) antibodies and thymoma appear to be at higher risk. Most episodes of MC do not occur suddenly, providing a window of opportunity for prevention. ...
MG patients with a history of MC, severe disease, oropharyngeal weakness, muscle-specific kinase (MuSK) antibodies and thymoma appear …
Diagnosis and Management of Myasthenia Gravis.
Hehir MK 2nd, Li Y. Hehir MK 2nd, et al. Continuum (Minneap Minn). 2022 Dec 1;28(6):1615-1642. doi: 10.1212/CON.0000000000001161. Continuum (Minneap Minn). 2022. PMID: 36537972 Review.
Data on rituximab suggest that it can be a good option, especially for patients with MG who are positive for antibodies against muscle-specific tyrosine kinase (MuSK). The number of clinical trials and drugs in development for MG is steadily increasing. ...
Data on rituximab suggest that it can be a good option, especially for patients with MG who are positive for antibodies against muscle-speci …
Musk ketone induces apoptosis of gastric cancer cells via downregulation of sorbin and SH3 domain containing 2.
An J, Wang H, Ma X, Hu B, Yan Y, Yan Y, Su Z. An J, et al. Mol Med Rep. 2021 Jun;23(6):450. doi: 10.3892/mmr.2021.12089. Epub 2021 Apr 21. Mol Med Rep. 2021. PMID: 33880576 Free PMC article.
Musk ketone exerts antiproliferative effects on several types of cancer, such as lung and breast cancer. However, the effects and underlying mechanisms of action of musk ketone in gastric cancer (GC) are poorly understood. The present study aime …
Musk ketone exerts antiproliferative effects on several types of cancer, such as lung and breast cancer. However, the e …
Myasthenia gravis: a clinical-immunological update.
Binks S, Vincent A, Palace J. Binks S, et al. J Neurol. 2016 Apr;263(4):826-34. doi: 10.1007/s00415-015-7963-5. Epub 2015 Dec 24. J Neurol. 2016. PMID: 26705120 Free PMC article. Review.
Diagnosis and treatment of myasthenia gravis.
Mantegazza R, Cavalcante P. Mantegazza R, et al. Curr Opin Rheumatol. 2019 Nov;31(6):623-633. doi: 10.1097/BOR.0000000000000647. Curr Opin Rheumatol. 2019. PMID: 31385879 Review.
Clinical trials on the use of biological drugs were recently concluded, providing important data on safety and efficacy of eculizumab, efgartigimod and amifampridine phosphate: the first, a complement blocker, showed long-term safety and efficacy in acetylcholine receptor (AChR)- …
Clinical trials on the use of biological drugs were recently concluded, providing important data on safety and efficacy of eculizumab, efgar …
Rituximab treatment of myasthenia gravis: A systematic review.
Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Tandan R, et al. Muscle Nerve. 2017 Aug;56(2):185-196. doi: 10.1002/mus.25597. Epub 2017 Mar 21. Muscle Nerve. 2017. PMID: 28164324 Review.
Posttreatment relapses decreased more in MuSK MG (P = 0.05). Response predictors were MuSK MG, less severe disease, and younger age at treatment. Among a responder subset, 26% of AChR and 82% of MuSK MG patients showed decreased posttreatment antibody titers. …
Posttreatment relapses decreased more in MuSK MG (P = 0.05). Response predictors were MuSK MG, less severe disease, and younge …
1,139 results